Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523654 | 1.00 | NOTUM (1.00) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL2586534 | 1.00 | NOTUM (1.00) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL20462830 | 0.86 | NOTUM (0.75) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL1865732 | 0.84 | NOTUM (0.73) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL8057268 | 0.84 | NOTUM (0.73) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL1825815 | 0.83 | NOTUM (0.71) | NOTUMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17018045 | 0.83 | NOTUM (0.71) | NOTUMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30366703 | 0.83 | NOTUM (0.71) | NOTUMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21172540 | 0.83 | NOTUM (0.71) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL21172704 | 0.83 | NOTUM (0.71) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014160478-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| US-8692001-B2 | Sulfonamides for the modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2014-04-08 | — | — | US | disclosed |
| WO-2012056319-A1 | SULFONAMIDES FOR THE MODULATION OF PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-05-03 | — | — | US | disclosed |
| US-20100204282-A1 | Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors | AMIRA PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2008097930-A1 | REVERSE INDOLES AS 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2007-11-22 | — | — | US | disclosed |
| US-7262297-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204282-A1 | Reverse indoles as 5-lipoxygenase-activating protein (FLAP) inhibitors | ALOX5, LTC4S, LTA4H | NOTUM 302/4885ALDH1A1 1773/4885NPC1 3445/4885 |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | NOTUM 1324/4885ALDH1A1 514/4885NPC1 52/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | NOTUM 2116/4885ALDH1A1 374/4885NPC1 2977/4885 |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | NOTUM 2496/4885ALDH1A1 1206/4885NPC1 2521/4885 |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | NOTUM 4317/4885ALDH1A1 967/4885NPC1 4325/4885 |
| US-20120108631-A1 | Sulfonamides for the Modulation of PKM2 | PDK1, PDK4, PDK2 | NOTUM 3880/4885ALDH1A1 2275/4885NPC1 4412/4885 |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | NOTUM 1324/4885ALDH1A1 514/4885NPC1 52/4885 |
| US-20070270445-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, DUSP15, PPP5C | NOTUM 3091/4885ALDH1A1 1309/4885NPC1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.